The ongoing multicenter open-label adaptively randomized phase 2 I-SPY2 trial is currently investigating dual immune blockade with cemiplimab plus the investigational agent REGN3767 as neoadjuvant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback